India Pharma Outlook Team | Wednesday, 18 November 2026
Aragen’s biologics manufacturing is set to expand as Aragen Life Sciences plans to invest approximately Rs 1,500 crore over the next three years across its drug discovery, development and manufacturing operations.
The Hyderabad-based company aims to increase its biologics manufacturing capacity from 2.5 kiloliters (KL) to 8.5 KL, according to its managing director and CEO, Manmahesh Kantipudi.
The investment comes as the company prepares for its proposed initial public offering (IPO) and seeks to expand its contract development and manufacturing organization (CDMO) business amid growing global outsourcing demand.
Also Read: How Digital R&D Is Transforming API Development and cGMP Scale-Up in India
Aragen’s biologics manufacturing expansion will increase installed capacity to 8.5 KL from 2.5 KL. The company’s official website confirms that its existing 2.5 KL GMP manufacturing facility was operational as of March 31, 2026.
Its Bengaluru facility provides integrated biologics development and manufacturing services, covering cell-line development, process development, analytical services and GMP production.
This gene-to-GMP model allows pharmaceutical and biotechnology companies to work with one partner across different stages of drug development.
Of the planned Rs 1,500 crore investments, approximately Rs 1,000 crore will support CDMO operations, while Rs 400 crore will go towards discovery and contract research.
Aragen currently generates around 65 percent of its revenue from drug discovery services. CEO Manmahesh Kantipudi mentioned that the company sees significant room to grow its CDMO business by expanding relationships with existing customers.
Aragen’s biologics manufacturing strategy reflects its focus on capturing more development and production work as global pharmaceutical companies diversify outsourcing and supply chains.